

**Remarks**

Claims 1-11 are pending in the subject application. Applicants have hereinabove amended claims 1, 2, 6 and 11. Applicants respectfully submit that amended claims 1, 2, 6 and 11 do not contain new matter and are fully supported by the specification as filed. Applicants respectfully request entry of this Amendment and reconsideration of the application as amended.

Claim 1 has been amended to include the recited definition of Z from claim 2. Support for the amendment to claim 1 can be found for example in claim 2; on page 3, lines 26-28, referring to wherein Z in formula 1 can be a pyridine or a thiophene group; and on page 4, lines 5-7, referring to wherein Z in formula 2 can be a pyridine or a thiophene group. Claims 2 and 6 have been amended to delete that part of the limitation that is included in claim 1. Claims 2 and 6 both depend from claim 1. Support for the amendment to claim 11 can be found for example on pages 21-24, referring to pharmaceutical compositions.

**1. Rejection under 35 U.S.C. §102(b)**

On page 2 of the Action, claims 1, 3-5, 7 and 9-11 stand rejected under 35 U.S.C. 102(b) as being anticipated by Venet (US Patent #5,968,952). The Examiner asserts that the teaching of Venet in example 83 on column 33 is encompassed by the instant claims. The Examiner asserts Venet's equivalent to Z to be benzodioxol, which the Examiner further asserts is a 9-membered heterocyclic that is substituted with 1-4 R<sup>3</sup> groups wherein R<sup>3</sup> is hydrogen. The Examiner has indicated that claims limited to Z being pyridine or thiophene would be free of prior art. Applicants have amended claim 1 to recite that Z is a pyridine or a thiophene that is optionally substituted with 1 to 4 R<sup>3</sup> substituents. Support for the amendment to claim 1 can be found for example in claim 2; on page 3, lines 26-28, referring to wherein Z in formula 1 can be pyridine or a thiophene group; and on page 4, lines 5-7, referring to wherein Z in formula 2 can be a pyridine or a thiophene group. The present amendment to claim 1 is believed to overcome the present rejection. Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw his rejection under 35 U.S.C. 102(b)

**2. Rejection under 35 U.S.C. §112, Second Paragraph**

On page 3 of the Action, Claims 1, 2, 6 and 8 stand rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention. Applicants' amendments and/or arguments below are believed to overcome the present rejection.

With regard to claim 1, the Examiner asserts that this claim is ambiguous due to its reciting (on 13<sup>th</sup> and 14<sup>th</sup> line of this claim) "except H but including any optional fused rings referred to above". Applicants respectfully disagree with the Examiner's rejection of the aforementioned phrase. The claim is not ambiguous; rather the inclusion of the phrase leave no ambiguity that the optional substituent R<sup>3</sup>

may be a substituent on each of the recited  $R^1$  groups  $C_1$ - $C_{10}$  alkyl,  $-(CR^{11}R^{12})_qC(O)R^{10}$ ,  $-(CR^{11}R^{12})_qC(O)OR^9$ ,  $-(CR^{11}R^{12})_qOR^{10}$ ,  $-(CR^{11}R^{12})_qC(R^{11})(R^{12})SO_2R^9$ ,  $-(CR^{11}R^{12})_q(C_3-C_{10} \text{ cycloalkyl})$ ,  $-(CR^{11}R^{12})_q(C_6-C_{10} \text{ aryl})$ , and  $-(CR^{11}R^{12})_q(4 \text{ to } 10 \text{ membered heterocyclic})$  **and on any of the optionally fused rings** to the recited  $R^1$  cycloalkyl, aryl and heterocyclic. The inclusion of the rejected phrase makes it crystal clear where substituent  $R^3$  may be placed. Accordingly, applicants respectfully submit that the phrase provides definiteness to the claim, not indefiniteness. Applicants respectfully request the Examiner reconsider and withdraw his rejection. With regard to claims 2 and 6, the Examiner asserts that these claims are ambiguous owing to the recitation (in the second line of this claim) “Z is a pyridine or thiophene group, including pyridine or thiophene groups substituted with . . .”. The Examiner has suggested that this phrase should be rewritten to state “Z is a pyridine or thiophene optionally substituted with 1-4  $R^3$  substituents. Applicants’ amendment of claim 1 is believed to overcome this rejection, as claims 2 and 6 depend from claim 1.

With regard to claim 8, the Examiner asserts that this claim is ambiguous due to the claim being drawn to a compound but having the word “and” on line 11 of the claim. The Examiner asserts that this leads to the claim being a composition and suggests that the claim be rewritten to have “or” in place of “and”. Applicants respectfully disagree with the position taken by the Examiner and traverse this rejection of claim 8. Applicants respectfully point out that Markush language is employed in claim 8, and the use of the term “and” between the penultimate and ultimate groups of said Markush group is proper. Thus claim 8 does not refer to a composition as suggested by the Examiner but to a **compound** selected from the **group consisting of** the listed compounds **and** the pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds as recited in this claim. It is respectfully submitted that such recitation represents the correct and proper use of Markush language. Accordingly, Applicants respectfully request the Examiner to withdraw her rejection of this claim.

### **3. Rejection under 35 U.S.C. §112, First Paragraph Written Description**

On pages 3-4 of the Action, claims 10-11 have been rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the written description requirement. The Examiner alleges that these claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The Examiner asserts that the instant specification does not adequately describe the nexus between the inhibition of the Ras farnesylation receptor and a useful treatment of abnormal cell growth and the treatment of cancers.

Applicants respectfully disagree with the position taken by the Examiner and traverse this rejection.

There is a strong presumption that an adequate written description of the claimed invention is present when the application is filed. *In re Wertheim*, 541 F.2d 257, 263, 191 USPQ 90, 97 (CCPA 1976)

("we are of the opinion that the PTO has the initial burden of presenting evidence or reasons why persons skilled in the art would not recognize in the disclosure a description of the invention defined by the claims"). MPEP 2163.

An objective standard for determining compliance with the written description requirement is, "does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed. The test for sufficiency of support in a parent application is whether the disclosure of the application relied upon "reasonably conveys to the artisan that the inventor had possession at that time of the later claimed subject matter." *Ralston Purina Co. v. Far-Mar-Co., Inc.*, 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed. Cir. 1985) (quoting *In re Kaslow*, 707 F.2d 1366, 1375, 217 USPQ 1089, 1096 (Fed. Cir. 1983)). MPEP 2163.02.

It is respectfully submitted that the Examiner's assertion that the instant specification does not adequately describe the nexus between the inhibition of the Ras farnesylation receptor and a useful treatment of cancer is not well founded. Applicants state (on page 1, lines 20-26 of the instant application):

Mutated, oncogenic forms of Ras are frequently found in many human cancers, most notably in more than 50% of colon and pancreatic carcinomas (Kohl *et al.*, *Science*, Vol. 260, 1834 to 1837, 1993). The compounds of the present invention exhibit activity as inhibitors of the enzyme farnesyl protein transferase and are therefore believed to be useful as anti-cancer and anti-tumor agents.

Applicants have therefore provided reasonable basis for their assertion that inhibition of farnesyl protein transferase is linked to the treatment of cancer. Furthermore, prior to the filing of the present application, it has been well known to those of ordinary skill in the art, that farnesyl transferase inhibitors can be useful as anticancer agent. Applicants respectfully direct the Examiner's attention to International patent publication WO 97/16443 (published May 9, 1997) which published prior to the filing of the present application and which has been cited as a reference by the Examiner in the instant case. On page 1, lines 9-31 of WO 97/16443, it is stated:

Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis.

Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells. Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer. A particular group of oncogenes is known as ras which have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts. The family of mammalian ras oncogenes consists of three major members ("isoforms"): H-ras, K-ras and N-ras oncogenes. These ras oncogenes code for highly related proteins generically known as p21<sup>ras</sup>. Once attached to plasma membranes, the mutant or oncogenic forms of p21<sup>ras</sup> will provide a signal for the transformation and uncontrolled growth of malignant tumor cells. To acquire this transforming potential, the precursor of the p21<sup>ras</sup> oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Therefore, inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase, will prevent the membrane attachment of p21<sup>ras</sup> and block the aberrant growth of ras-transformed tumors. Hence, it is generally accepted in the art that farnesyl transferase inhibitors can be very useful as anticancer agents for tumors in which ras contributes to transformation.

Since mutated, oncogenic forms of ras are frequently found in many human cancers, most notably in more than 50% of colon and pancreatic carcinomas (Kohl et al., Science, vol 260, 1834-1837, 1993), it has been suggested that farnesyl transferase inhibitors can be very useful against these types of cancer.

Applicants assert that the present specification in combination with the state of the art at the time of filing the present application clearly indicate that the Applicants were in possession of the invention as claimed in claims 10-11. Accordingly, Applicants respectfully request the Examiner to withdraw this rejection.

**4. Rejection under 35 U.S.C. §112, First Paragraph Enablement**

On pages 4-8 of the Action, claims 10-11 stand rejected under 35 U.S.C. §112, first paragraph, as allegedly failing with comply with the enablement requirement. The Examiner alleges that these claims contain subject matter which was not described in the specification in such a way as to enable one skilled

in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The Examiner asserts that one of ordinary skill in the art would have to engage in undue experimentation to test which diseases can be treated by the compounds of the instant claims, with no assurance of success. For the reasons that follow, Applicants respectfully traverse this rejection and request that it be withdrawn.

Applicants respectfully submit that the Examiner has failed to make a *prima facie* case of non-enablement for the pending claims of the subject application under 35 U.S.C. §112, first paragraph that is well-grounded in scientific reasoning or evidence. The Examiner has failed to set forth a reasonable explanation as to why he believes that the scope of protection is not adequately enabled by the description of the invention provided in the specification. In order to make a §112, first paragraph rejection the Examiner has the initial burden to establish a reasonable basis to question the enablement provided for the claimed invention. *In re Wright*, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993) (examiner must provide a reasonable explanation as to why the scope of protection provided by a claim is not adequately enabled by the disclosure).

The CCPA has stated that “it is incumbent upon the Patent Office, whenever a rejection on this basis [35 U.S.C. 112, first paragraph] is made, to explain *why* it doubts the truth or accuracy of any statement in a supporting disclosure and to back up assertions of its own with acceptable evidence or reasoning which is inconsistent with the contested statement. Otherwise, there would be no need for applicant to go to the trouble and expense of supporting his presumptively accurate disclosure.” *In re Marzocchi*, 169 USPQ 368, 370 (CCPA 1971). Applicants respectfully submit that the Examiner has failed to meet his burden and has neither provided evidence or reasoning, which would support his assertion that the claims of the subject application are not enabled.

The Examiner has rejected the claims of the subject application by asserting that one of ordinary skill in the art would have to engage in undue experimentation to test which diseases can be treated by the compounds of the instant claims, with no assurance of success.

The specification clearly sets forth on page 1, that the compounds of the present application inhibit the enzyme farnesyl protein transferase and that such activity has been correlated with the treatment of cancers and tumors. Applicants reiterate their arguments set forth above under “written description” to support their position that it is well known that inhibition of farnesyl protein transferase will be useful in the treatment of abnormal cell growth and cancer. Applicants respectfully submit that a large number of compounds having tyrosine kinase inhibitory properties have been identified in the art. In this regard, applicants direct the Examiner’s attention to the present application, page 1, line 27 to page 2, line 3, which lists patent applications describing compounds having activity inhibiting farnesyl protein transferase. Applicants are also attaching herewith a review article entitled Inhibitors in protein farnesylation 1998 in the journal Expert Opinion on Therapeutic Patents (1998) 8 (5), which is a review of different types of protein farnesyltransferase inhibitors prior to the filing of the present application.

Applicants respectfully submit that there is a high level of expertise in the field of the present invention. Applicants also respectfully submit that the specification of the claimed invention coupled with the high degree of expertise in the field of farnesyl transferase inhibitors enables one of ordinary skill in the art to practice the claimed invention.

The Examiner has offered no objective evidence for his position that the claimed invention is not enabled. The Examiner has merely offered his opinion without any documented support for such a position. The Examiner's position is contrary to the understanding of those of ordinary skill in art as indicated and shown by the multitude of patent applications directed to compounds useful in the treatment of abnormal cell growth. The specification teaches that all the compounds employed in the pharmaceutical compositions and methods of these claims are inhibitors of the enzyme farnesyl protein transferase and that they are useful in treating abnormal cell growth including cancer. The Examiner has not proffered any evidence to show that those skilled in the art would doubt the objective truth of these statements. Therefore, such statements must, as indicated above, be accepted as true.

On pages 24-25 of the specification, Applicants provide further guidance for those skilled in the art to assess the activity of the compounds falling within the scope of the present invention using the recited *in vitro* and *in vivo* tests. Moreover, pages 22 and 23 of the specification describe how the methods of claimed invention can be carried out by those skilled in the art. It specifies, on these pages, appropriate dosages and methods of administration. This description includes the various modes by which the compounds employed in the claimed methods can be administered to mammals, the pharmaceutically acceptable forms in which they can be administered and appropriate dosages for their administration. The foregoing information is sufficient to enable one skilled in the art to practice the inventions of each of the pending claims and thus complies with the requirements of 35 U.S.C. §112, first paragraph.

A specification disclosure that contains a teaching of the manner and process of making and using the invention in terms that correspond in scope to those used in describing and defining the subject matter sought to be patented must be taken as in compliance with enabling requirement of the first paragraph of §112 unless there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support. *In re Marzocchi*, 169 U.S.P.Q. 367, 369 (C.C.P.A. 1971). Further, the burden is on the Examiner to come forth with evidence to establish a *prima facie* case of non-enablement. *In Re Armbruster*, 185 U.S.P.Q. 152, 153 (C.C.P.A. 1975); *In re Marzocchi*, 169 U.S.P.Q. at 370. The Examiner has not proffered any evidence, merely her opinion and a boilerplate list of factors for the lack of enablement of the claimed invention.

Applicants believe it is incontrovertible that those of ordinary skill in the art accepted that development of inhibitors of protein farnesyl transferase would be useful in the treatment of cancer as presently claimed. The Examiner has offered no objective evidence, which would contradict or question this understanding in the art at the time the filing of the subject application. Applicants respectfully

request that the Examiner reconsider and withdraw his rejection of claims 10-11 under 35 U.S.C. §112, first paragraph for the reasons set forth above.

With regard to claim 11, the Examiner has stated on page 8 of the Action, that she has included this claim in this rejection because the pharmaceutical composition is for use in the treatment of abnormal cell growth. She has indicated that a claim limited to the pharmaceutical composition of a compound of claim 1 and an acceptable pharmaceutical carrier would be in better condition for allowance. While Applicants do not concede that claim 11 is not allowable as originally written and have indeed traversed the present enablement rejection of this claim above, to advance prosecution, Applicants have amended this claim in the manner suggested by the Examiner. Accordingly, amended claim 11 is deemed to overcome this rejection.

On pages 8-13 of the Action, claims 1, 3-5, 7 and 9-11 stand rejected under 35 U.S.C. §112, first paragraph, as allegedly failing with comply with the scope of enablement requirement. The Examiner asserts that Z is enabled by the instant specification to the extent that Z is optionally substituted pyridine or thiophene; however, all heterocyclic groups are not enabled. The Examiner has indicated that this rejection can be overcome by amending Z to be a pyridine or thiophene. Applicants' amendment of claim 1 (all other claims depend from claim 1) wherein Z has amended to be a pyridine or thiophene group is deemed to overcome this rejection.

#### CONCLUSION

Applicants respectfully request prompt consideration of the pending claims and early allowance of the application.

If the Examiner wishes to comment or discuss any aspect of this application or response, applicants' undersigned attorney invites the Examiner to call him at the telephone number provided below.

Date: July 29, 2004

Pfizer, Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5612  
(212) 733-5310

Respectfully submitted,

Krishna G. Banerjee  
Krishna G. Banerjee  
Attorney for Applicant(s)  
Reg. No. 43,317



<http://www.ashley-pub.com>

## Update

- 1 New biology
- 2 PFTase inhibitors competitive with protein
- 2.1 Inhibitors with a thiol group
- 2.2 Inhibitors without a thiol group
- 3 Farnesyl pyrophosphate analogues and antagonists
- 4 PFTase inhibitors with an undefined enzyme inhibitory mechanism
- 5 Conclusion
- 6 Expert opinion
- Acknowledgements
- Bibliography
- Patents
- References to the internet

## Inhibitors of protein farnesylation 1998

Theresa M Williams

Department of Medicinal Chemistry, Merck Research Laboratories,  
West Point, PA 19438, USA

Protein farnesyltransferase (PFTase) inhibitors are being studied as mechanistically novel antitumour agents. Whilst the antiproliferative effects of PFTase inhibitors are well-documented in cell culture and rodent animal models, clinical studies which began in 1997 should soon reveal their utility in human cancer patients. This review summarises the scientific and patent literature covering PFTase inhibition that has been published since the previous two updates [1,2]. New biology with a potential impact on the utility of PFTase inhibitors is reviewed first, followed by a discussion of new PFTase inhibitors. As in earlier updates, compounds are grouped according to their kinetic mechanism of PFTase inhibition.

**Keywords:** PFTase, protein farnesyltransferase, protein farnesyltransferase inhibitors, protein prenylation, ras oncogene


*Exp. Opin. Ther. Patents (1998) 8(5):553-569*

### 1. New biology


Interest in PFTase inhibitors began when it was determined that the protein product of the *ras* oncogene was a PFTase substrate [1]. Since then, studies in genetically engineered and human tumour cell lines with *ras* mutations have demonstrated that PFTase inhibitors suppress Ras farnesylation and function as antiproliferative agents [3]. The presence of a *ras* mutation is not a prerequisite for growth inhibition, since human tumour cell lines with either mutant or wild-type *ras* are sensitive to the antiproliferative effect of PFTase inhibitors [4,5]. It is possible that this added sensitivity is due in part to blocking prenylation of other (non-Ras) PFTase protein substrates involved with mitogenesis. *In vivo*, PFTase inhibitors suppress *ras*-dependent tumour growth in mice. Experiments in H-*ras* transgenic mice showed that **L-744,832** regressed tumours when administered subcutaneously once daily [6]. More recently, tumours in H-*ras* transgenic mice with an additional genetic defect, such as loss of the p53 tumour suppressor gene or deregulated *myc* transcriptional activation, regressed upon similar treatment with **L-744,832** [7]. The exact mechanism of tumour regression during PFTase inhibitor treatment has not been elucidated, although it may involve apoptosis [8]. Collectively, these results suggest a range of human tumours that might respond to PFTase inhibitor therapy. Synergy between PFTase inhibitors and other chemotherapeutic agents may further extend the therapeutic potential. Careful preclinical evaluation of drug combinations is warranted, since a study examining the effect of **BZA-5B** in combination with cisplatin unexpectedly found that **BZA-5B** actually induced cisplatin resistance in a melanoma cell line with an N-*ras* mutation [9].

Cells with overexpressed H-*ras* were known to be much more sensitive to the effects of PFTase inhibitors than cells with overexpressed K-*ras*, which







**L-744,832** R = CH(CH<sub>3</sub>)<sub>2</sub>  
**L-739,749** R = CH<sub>3</sub>  
 PFTase IC<sub>50</sub> R = H 0.3 nM




**BZA-5B** R = CH<sub>3</sub>  
 PFTase IC<sub>50</sub> R = H 0.3 nM




**HR-11** R = H PFTase IC<sub>50</sub> 1.2 nM  
**HR-12** R = CH<sub>3</sub>




**(+) isomer R115777**  
 PFTase IC<sub>50</sub> 2 nM




**SCH 66336**  
 PFTase IC<sub>50</sub> 2 nM



**RPR 113829** R = H PFTase IC<sub>50</sub> 1.8 nM  
**RPR 114334** R = CH<sub>3</sub>



**SCH 44342**  
 PFTase IC<sub>50</sub> 250 nM



**B956**  
 PFTase IC<sub>50</sub> 11 nM

is the most prevalent *ras* mutation in human tumours. It was subsequently found that K-Ras is not only farnesylated by PFTase, but is also geranylgeranylated by protein geranylgeranyltransferase I (GGTase I) *in vitro*. Since geranylgeranylated K-Ras is thought to retain some biological activity, the alternative prenylation pathway might be responsible for the decreased sensitivity to PFTase inhibitors in K-Ras transformed cells. Direct evidence for the geranylgeranylation of K-Ras in cells treated with PFTase inhibitors has been obtained. HPLC analysis showed that geranylgeranylated K-Ras is present in cells treated with **B956** [10] or **SCH 44342** [11] and [<sup>3</sup>H]-mevalonolactone, whereas exclusively farnesylated K-Ras is present in untreated cells. Although the relationship between the overall prenylation status of H- or K-Ras and tumour growth needs further study, it is interesting to note that distinct biological functions for H-Ras and K-Ras may exist. The first evidence for this is a prenylation-dependent binding of K-Ras with microtubules which does not occur with H-Ras [12]. In addition to

prenylation, an intact CaaX box was required for K-Ras microtubule binding. Association of prenylated K-Ras with the plasma membrane was disrupted in cells treated with Taxol (paclitaxel). This suggests either that microtubules are involved with delivering K-Ras to the plasma membrane, or that prenylated (but not fully processed) K-Ras has some unknown function related to microtubules.

Clinical trials with two PFTase inhibitors, **R115777** and **SCH 66336**, were initiated in 1997 by Janssen (in conjunction with the National Cancer Institute [201]) and Schering-Plough, respectively [13-15]. Preliminary results from these trials are scheduled to become public in 1998. In a related study, Isis Pharmaceuticals began clinical trials with an antisense oligodeoxynucleotide designed to block expression of the *H-ras* gene *in vivo* [16]. It will be interesting to compare the results of the *ras* antisense trial, designed to block the activity of one farnesylated protein, with results from

PFTase inhibitor clinical trials, which will affect the activity of multiple PFTase protein substrates.

A number of studies offer evidence that Ras is not the only PFTase substrate responsible for the antiproliferative effect of PFTase inhibitors in transformed cells [17,18]. While Ras is an integral part of the MAP kinase signalling pathway, RhoB, a small GTP-binding protein which is both farnesylated and geranylgeranylated, is part of a related signalling pathway involved with focal adhesion assembly and actin cytoskeleton organisation. The PFTase inhibitor **L-739,749** was recently shown to block the farnesylation of RhoB both *in vitro* and in intact cells, and to inhibit RhoB-dependent cell growth [19]. In this experiment, the level of geranylgeranylated RhoB increased as farnesylated RhoB decreased. Other PFTase substrates which may play a role in the antiproliferative effects of PFTase inhibitors include RhoE [20], RheB [21,22], and the protein tyrosine phosphatases PRL-1 [23,24], and IP3 5-PTPase [25].

An x-ray crystal structure of wild-type rat PFTase was determined at 2.25 Å resolution [26,27]. The structure, composed of  $\alpha$  and  $\beta$  subunits, consists of a seven-helix hairpin domain and an  $\alpha$  helical barrel structure thought to be the farnesylpyrophosphate (FPP) binding site. The catalytic zinc ion is positioned at the entrance to the  $\alpha$ - $\alpha$  barrel, lending support to this interpretation. Mutational analysis of conserved residues in the  $\beta$ -subunit of PFTase confirm structural evidence that residues His<sup>248</sup>, Arg<sup>291</sup>, Lys<sup>294</sup> and Trp<sup>303</sup> are involved with binding FPP, and that Cys<sup>299</sup>, Asp<sup>297</sup> and His<sup>362</sup> are ligands for the catalytic zinc cation [28]. Point mutation also determined that Arg<sup>202</sup> is a critical residue for binding the C-terminal carboxylate of the protein substrate.

## 2. PFTase inhibitors competitive with protein

### 2.1 Inhibitors with a thiol group









The C-terminal tetrapeptide of Ras comprises a CaaX motif found in many proteins that are substrates for prenyltransferases (C = cysteine, a = any aliphatic amino acid, X = serine or methionine for PFTase substrates; X = leucine for PGGTase I substrates). Enzyme substrates undergo farnesylation of the cysteine thiol of the CaaX sequence. Early studies established that tetrapeptides corresponding to the C-terminus of the Ras protein were Ras-competitive

inhibitors of PFTase. Much about the biological consequences of PFTase inhibition was first revealed by studying tetrapeptide and modified tetrapeptide inhibitors. Since the genesis and evolution of protein substrate-based inhibitors are the subject of earlier reviews, only the most recent extensions of this work are summarised below [3,29].

Transposing the hydrophobic sidechains in the tetrapeptide inhibitor Cys-Val-Phe-Met (CVFM) from C $\alpha$  to N, investigators at the Hebrew University of Jerusalem report a series of highly potent PFTase inhibitors that are structurally related to compounds disclosed in a Merck patent application [30,101]. The N-benzyl glycine analogue **1** was only 2-fold less active than the parent CVFM. The most potent compound in the series, **HR-11** inhibited PFTase with an IC<sub>50</sub> of 1.2 nM, while the methyl ester prodrug **HR-12** blocked farnesylation in v-H-ras transformed NIH-3T3 cells with an IC<sub>50</sub> of 10  $\mu$ M. As with the parent CVFM tetrapeptide, these compounds were not substrates of the enzyme and were highly selective for the inhibition of PFTase over PGGTase I.

In a scientific paper, researchers at Rhône-Poulenc Rorer discuss conformationally restricted naphthalene-containing CaaX analogues, inhibitors previously disclosed in patent applications [31]. Both 1,5- (**2a**) and 1,6- (**RPR 113829**) substituted naphthalenes fit the authors' pharmacophore model of an extended, biologically active conformation which is consistent with observations from the group formerly at the University of Pittsburgh [32-34]. These compounds inhibited PFTase with IC<sub>50</sub> values of 5.6 nM (**2a**) and 1.8 nM (**RPR 113829**). As with many carboxylate PFTase inhibitors, the parent acids did not suppress farnesylation in cell culture, although the corresponding methyl ester prodrugs **2b** and **RPR 114334** showed 20 - 50% inhibition of Ras farnesylation in CCL39 cells transfected with activated H-ras. **RPR 114334** inhibited anchorage-independent cell growth in genetically engineered and human tumour cell lines, suppressing colony formation with IC<sub>50</sub> values of 5  $\mu$ M and 10  $\mu$ M for H- and K-ras transfected NIH-3T3 cells, respectively, and 5  $\mu$ M (H 460 cells) and 50  $\mu$ M (HCT 116 cells) for two human tumour cell lines containing K-ras mutations. A Rhône-Poulenc Rorer patent application claims 1,4-substituted naphthalenes (**3**) as PFTase inhibitors [102].

The same group also describes modifications to the N-terminus of Cys-Val-Tic-Met (**4**) intended to stabilise the tetrapeptide towards proteolytic




degradation [35]. N-Acylated tetrapeptides such as **5** had *in vitro* potencies similar to the parent tetrapeptide **4**, but were more stable to incubation with CCL39 cell extract. Despite the increase in stability, these compounds were still not active in cell culture, perhaps reflecting poor permeability of cell membranes. Ester prodrugs of **5** were not reported. Peptide backbone modifications, such as inverting the peptide attachment of **6** [36] to give **7** or reduction of the Tic-Met amide bond, were poorly tolerated in terms of *in vitro* potency [35].

A patent application discloses that Zeneca combined the 2(*R*)-mercaptopyrrolidine cysteine replacement (also used as a constrained cysteine residue by Bristol-Myers Squibb [37] with a diphenylmethylcarboxamide α<sub>1</sub>α<sub>2</sub> surrogate, giving **8** [103]. Biological data was not reported.

To examine the possibility of product feedback inhibition, investigators at the Universität Karlsruhe synthesised (*S*)-farnesylated peptides corresponding to the C-terminal tri- and pentapeptide sequence of the fully processed N-Ras protein [38]. While not inhibiting PFTase up to millimolar concentrations, extension to the farnesylated and palmitoylated hexapeptide **9** revealed weak inhibition.

Non-peptide, diarylether PFTase inhibitors comprise the subject of a recent communication from Merck [39]. Structurally related to biarylcarboxylate inhibitors published earlier [40,41], diarylether carboxylates **10a,b** and **11a,b** were moderately active *in vitro*, and demonstrated a preference for the *m,m*-substitution pattern. The methyl ester of **10b** blocked the anchorage-independent growth of H-ras transformed cells in soft agar with an IC<sub>50</sub> of 10 - 30 μM. Replacing the carboxylate group of **10a** with a methyl group did not substantially change the IC<sub>50</sub> value, indicating the carboxylic acid was not optimally positioned to interact with PFTase Arg<sup>202</sup>, the residue identified by mutational analysis to bind the C-terminal carboxylic acid in CaaX analogues [28]. Non-peptide N-phenylbenzamide PFTase inhibitors such as **12** are disclosed in a patent application from Merck, but specific biological data was not given [104]. A patent application from Biomeasure, Inc. covers imidazopiperazine PFTase inhibitors **13** and claims antiproliferative activity vs. a number of cell lines with mutated K-ras (A-427, Calu-1, MIA-PaCa) or wild-type K-ras (HT-29) [105].




## 2.2 Inhibitors without a thiol group


Concern about possible long-term adverse effects associated with a thiol dictates the absence of this functional group from a PFTase inhibitor intended for chronic administration. CaaX analogues with either pyroglutamate **14** [106] or imidazole **15** [107] in place of the usual N-terminal cysteine residue are the subjects of two patent applications. Inhibition potency was not stated.

While a number of cysteinyl replacements have appeared in the patent literature for CaaX analogues, PFTase inhibitors which are non-peptidic offer the best chance of obtaining a drug suited to oral administration. It is of no surprise then that pharmaceutical companies with PFTase inhibitor programmes have been concentrating in recent years on obtaining a non-peptide, non-thiol inhibitor suitable for clinical studies.


Several publications from Schering-Plough describe the synthesis and structure-activity studies of their previously reported non-peptide, non-thiol inhibitor **SCH 44342** [42,43]. **SCH 44342** competes with Ras binding to PFTase, and has an IC<sub>50</sub> of 250 nM. In cell culture, it suppressed farnesylation in monkey kidney Cos cells with an IC<sub>50</sub> of 1 µM. Although **SCH 44342** was 21% orally bioavailable in mice, its half-life was less than 10 min. Nonetheless, large oral doses of **SCH 44342** (100 mg/kg, bid) administered to nude mice with tumours from the human colorectal cell line SW-620 (containing a *K-ras* mutation) produced a 42% reduction in tumour weight after 35 days compared to vehicle control. The intrinsic potency of **SCH 44342** increased 6-fold by the addition of a methyl group at C-3 of the benzocycloheptapyridine ring. **SCH 56580** inhibited PFTase with an IC<sub>50</sub> of 40 nM, however it remains equipotent to **SCH 44342** in cell culture. Related inhibitors include 3-bromobenzo-




**SCH 59228**  
PFTase IC<sub>50</sub> 47 nM




**16a** X = CO PFTase IC<sub>50</sub> 0.8 μM  
**16b** X = SO<sub>2</sub> PFTase IC<sub>50</sub> 1 μM




**17**



**18**



**19**



**20**

cycloheptapyridine analogues described in a meeting poster [44]. The 4-N-methylpiperidinylacetyl PFTase inhibitor **SCH 59425** (PFTase IC<sub>50</sub> 120 nM) had 100% oral bioavailability and an 8.5 h half-life in mice, but had undesirable activity vs. muscarinic m<sub>1</sub> and m<sub>2</sub> receptors. The pyridylacetamide N-oxide **SCH 59228**, on the other hand, showed little m<sub>1</sub> and m<sub>2</sub> activity and was 38% orally bioavailable in cynomolgous monkeys, with a half-life of 2.6 h. **SCH 59228** inhibited PFTase with an IC<sub>50</sub> of 47 nM *in vitro*, 450 nM in Cos cells, and suppressed colony formation of H- and K-*ras* transformed NIH-3T3 cells with IC<sub>50</sub> values of 1.2 and 4 μM, respectively. In studies in nude mice, **SCH 59228** given 50 mg/kg qid for 3 - 4 weeks showed 71 - 95% inhibition of H-*ras* tumour growth. The same protocol resulted in 31 - 42% inhibition of SW-620 tumour growth. Acetamides and sulfonamides such as **16a** and **16b** were essentially equipotent, although substitutions in the acetamide series which increased potency (such as 3- and 4-pyridylacetamide) were not reported in the sulfonamide series [45]. Six patent applications from Schering-Plough [108-113] and one from Pharmacoepia [114] cover 3-bromo-8-chloro-benzopyridocycloheptane inhibitors such as **17-20**, with the structurally related diphenylacetyl piperazine N-pyridylacetamide **21** the subject of a separate Schering-Plough patent application [115]. Specific biological data was not mentioned. Clinical trials with an orally bioavailable inhibitor, **SCH 66336**, are underway; details of the compound are not known at this time [15].

### 3. Farnesyl pyrophosphate analogues and antagonists

Researchers at Parke-Davis have further elucidated the biological properties of pentapeptide **PD083176**, discovered by high volume screening of peptide libraries [46]. **PD083176** is a 20 nM inhibitor of PFTase, and is competitive with the FPP substrate. Although the peptide structure may make **PD083176** look more like a Ras protein competitive inhibitor, it is less surprising that the pentapeptide is competitive with the lipophilic FPP substrate when its many hydrophobic substituents are considered. Unable to suppress farnesylation in cell culture, the most reasonable explanation is poor membrane penetration since microinjection of **PD083176** into *Xenopus* oocytes inhibited insulin-induced *ras*-dependent



Table 1: IC<sub>50</sub> dependence on phosphate ion concentration.

[PO <sub>4</sub> <sup>2-</sup> ]	IC <sub>50</sub> (nM)			
	PD083176	22	23	24
0	1950	510	7.5	3400
5 mM	165	100	6.8	415
30 mM	20	40	ND	145




ND: Not determined.








maturation. Extensive SAR studies on **PD083176** revealed that substitution of Phe for Tyr(OBn) or L-Ala for D-Ala gave an approximate 2-fold increase in potency [46]. Curiously, *in vitro* activity of **PD083176** was dependent upon the concentration of phosphate anion in the assay mixture (Table 1) [47]. Both **PD083176** and the phenol **22** were more active under conditions in which phosphate anion was present than in phosphate-free conditions. It was speculated that anions such as phosphate bind at the enzyme active site and interact with **PD083176** to mimic an enzyme-product complex, which is consistent with the lack of phosphate-dependent activity of O-phosphotyrosine analogue **23**. The activity of truncated analogue **24** also showed a dependence on phosphate anion concentration; in the absence of phosphate, the IC<sub>50</sub> was 3.4 μM, while in 30 mM phosphate buffer the IC<sub>50</sub> dropped to 145 nM [48]. Compound **24** inhibited farnesylation in H-*ras* transfected NIH-3T3 cells with an IC<sub>50</sub> of 1 μM, which appears to be most consistent with the *in vitro* IC<sub>50</sub> determined in the presence of phosphate. Under assay conditions where **24** had an IC<sub>50</sub> of 320 nM (5 mM phosphate buffer), the 2,2-dimethyl phenethyl amide **25** was 100-fold more potent [49,116]. Most notably, **25** inhibited colony formation of H-*ras* transformed cells with an IC<sub>50</sub> of 180 nM, and blocked 88% of H-Ras tumour growth in nude mice when administered intraperitoneally at 150 mg/kg/day. Another patent application disclosed that histidine amide **26** had an IC<sub>50</sub> of 130 nM vs. PFTase, and inhibits Ras farnesylation in cell culture with an IC<sub>50</sub> of 2.5 μM [117].

Scientists at Istituto di Ricerca di Biologia Molecolare designed a synthetic tetrapeptide combinatorial library to screen for novel FPTase inhibitors which did not have a thiol functional group [50]. The most active peptide, D-tryptophan-D-methionine-D-4-chlorophenylalanine-L-γ-carboxyglutamic acid **27** was also



PD 083176 R = benzyl  
**22** R = H  
**23** R = PO<sub>3</sub><sup>2-</sup>

PFTase IC<sub>50</sub> 4 nM



**Table 2:** Activity and selectivity of chaetomelic acid analogues vs. yeast enzymes.

		IC <sub>50</sub>	PFTase	PGGTase
Chaetomelic acid	R = <i>n</i> -C <sub>14</sub> H <sub>29</sub>	17 μM	> 300 μM	
<b>31a</b>	R = farnesyl	2 μM	277 μM	
<b>31b</b>	R = geranylgeranyl	96 μM	11 μM	

competitive with respect to the FPP substrate, with a K<sub>i</sub> of 2 nM. The tetrapeptide selectively inhibited PFTase over PGGTase I (IC<sub>50</sub> 42 nM vs. > 50,000 nM).

Several publications describe the synthesis of benzophenone-containing analogues of FPP to use in photoaffinity labelling studies of yeast PFTase. Irradiation of yeast PFTase for 12 h in the presence of either isomer **28** (IC<sub>50</sub> 1600 nM) or **29** (IC<sub>50</sub> 850 nM) resulted in a 40% reduction in activity [51]. Compounds related to **28** and **29** were previously shown to label the β-subunit of yeast PFTase [52,53].

Building on earlier work [54,55], the FPP analogue 3-cyclopropyl-3-desmethylfarnesyl diphosphate **30a** was designed to be a mechanism-based inhibitor of PFTase [56]. It was envisioned that ionisation of the phosphate group in the enzyme active site to give the cyclopropylcarbanyl cation would result in alkylation and irreversible inhibition of the enzyme. Instead, however, **30a** effectively competed with FPP as an alternative substrate, with a K<sub>i</sub> of 500 nM. The more sterically demanding 3-*t*-butyl-3-desmethylfarnesyl diphosphate **30b** had a similar K<sub>i</sub> but was turned over exceptionally slowly by the enzyme. Time dependent inhibition of PFTase was not observed with either analogue.

A facile, two-step synthesis of the *bis*-carboxylic acid natural product chaetomelic acid A [57,58] and related analogues has appeared [59]. The farnesyl analogue **31a** (IC<sub>50</sub> 2 μM) was more potent vs. yeast PFTase than chaetomelic acid (IC<sub>50</sub> 17 μM) (Table 2). (Although these compounds were assayed for inhibition vs. yeast PFTase, note that chaetomelic acid is 300-fold more active vs. mammalian PFTase than yeast PFTase). Both chaetomelic acid and **31a** selectively inhibited PFTase over PGGTase I, however this selectivity was reversed for the geranylgeranylated

analogue **31b** (PGGTase IC<sub>50</sub> 11  $\mu$ M, PFTase IC<sub>50</sub> 96  $\mu$ M).


A sulfated tricarboxylic acid inhibitor of PFTase, oreganic acid, was isolated from fungal extracts [60,61]. It had an IC<sub>50</sub> of 14 nM vs. PFTase and 60  $\mu$ M vs. PGGTase and was competitive with the FPP substrate. Removal of the sulfate group or esterification of the carboxylic acids resulted in 100- to 1000-fold loss in potency.

#### 4. PFTase inhibitors with an undefined enzyme inhibitory mechanism


A number of interesting compounds have appeared in recent patent publications. Although biological data generally are not disclosed, many of the chemical structures lack both mercaptan and carboxylic acid groups and thus appear to be well suited to drug development programmes.

Patent applications from Janssen disclose two series of imidazolylmethyl quinolinone PFTase inhibitors **32** and **33** [118,119]. The only specifically claimed compounds were the two stereoisomers of **33**, one of which (the (+) isomer **R115777**) inhibited tumour growth of a cell line in nude mice when dosed at 25 mg/kg p.o. qid. Janssen is in clinical trials with **R115777**, which is being given by oral administration; **R115777** inhibits PFTase activity with an IC<sub>50</sub> of 7.9 nM and 40% of PGGTase activity at 50  $\mu$ M [13]. Initial studies indicate the compound is bioavailable in man, with a mean terminal half-life of 13 - 14 h. From the initial dose of 25 mg p.o. bid through 5 dose escalations, **R115777** showed acceptable toxicity, allowing further dose increases [14].

Additional imidazole-containing inhibitors were disclosed by Merck in patent applications. The imidazolylpropionamide bis pyrrolidine **34** and the N-imidazolylmethyl N-*p*-nitrobenzylamine **35** were claimed as PFTase inhibitors [120,121]. A series of patents have published claiming *p*-nitrobenzylimidazole or *p*-cyanobenzylimidazole attached to a number of different heterocycles, including piperazines related to **36** [122-126], piperidines similar to **37** [127-129], imidazolidinone **38** [130], biaryl and heterobiaryl compounds like **39** and **40** [131-138], benzodiazepinone **41** [139], and acyclic compounds related to **42** and **43** [140-147]. Specific biological data was not included in these patents. Imidazolylmethyl benzodiazepine **44** appears in a patent application








from Bristol-Myers Squibb, representing another class of imidazole-containing PFTase inhibitors [148].

Other interesting compounds published in the patent literature do not have an imidazole, but instead contain other nitrogenous heterocycles like pyridine. Patent applications from Pfizer disclose pyridylmethyl-substituted indolinones **45** [149] and **46** [150] as PFTase inhibitors. No biological data are given. The pyridyl-containing tricyclic dibenzodiazepine **47** ( $IC_{50}$  800 nM) is one of several specifically claimed PFTase inhibitors in a patent application from Warner-Lambert [151]. Tetracyclic benzo[*f*]isoindole compounds such as **48** ( $IC_{50}$  50 nM) comprise a patent application from Rhône-Poulenc Rorer [152].


A pharmacophore model correlating the activity of benzocycloheptapyridine PFTase inhibitors related to **SCH 44342** was generated by three-dimensional quantitative structure-activity relationship (3D-QSAR) computational analysis [62]. Using this hypothesis, three-dimensional search of the Schering-Plough database identified 718 hits. Biological testing ultimately identified imidazolylmethyl dihydrobenzothiophenes **49** ( $IC_{50}$  200 nM) and **50** ( $IC_{50}$  200 nM) as novel PFTase inhibitors. Despite their similar structures, **49** was only 3.5-fold selective for PFTase over PGGTase inhibition, while **50** was 84-fold selective. Other data, such as kinetic mechanism and cell potency, were not discussed.

A number of patent applications have appeared claiming di- and tricarboxylic acid PFTase inhibitors. Triaryl carboxylic acids **51-53** are disclosed in Banyu patent applications as having  $IC_{50}$  values of  $\leq 0.1$  nM [153-160]. Given its highly polar nature, it is somewhat surprising that tricarboxylic acid **51** displayed activity in cell culture, where it inhibited Ras processing with an  $IC_{50}$  of 3.5  $\mu$ M. Antitumour activity of **51** in a mouse tumour model was also observed. Cyclobutane di- and tricarboxylic acid PFTase inhibitors from Abbott (**54**) continue to appear in the patent literature [161,162]. Abbott has also claimed substituted pyromellitic acid **55** as a PFTase inhibitor which blocks Ras farnesylation by 98% at 1  $\mu$ M [163].


Kurasoins A and B are  $\alpha$ -hydroxyketones isolated from fermentation broths of a *Paecilomyces* sp. soil fungus, which inhibit PFTase with  $IC_{50}$  values of 59  $\mu$ M [63-65]. Additional members of the cylindrol and ascochlorin families of natural products (families associated with PFTase inhibitory activity) have been isolated from *Cylindrocarpon lucindum* and their PFTase activity characterised [66]. Compound **56** was




**49**  
PFTase IC<sub>50</sub> 200 nM




**50**  
PFTase IC<sub>50</sub> 200 nM




**51**  
PFTase IC<sub>50</sub> 0.1 nM




**52**




**53**  
PFTase IC<sub>50</sub> 0.1 nM




**54**  
81% inh PFTase @ 150 nM




**55**  
98% inh PFTase at 1 μM




**Kurasoin A**  
PFTase IC<sub>50</sub> 59 μM




**Kurasoin B**  
PFTase IC<sub>50</sub> 59 μM




**56**  
PFTase IC<sub>50</sub> 430 nM




**CP-225,917**  
PFTase IC<sub>50</sub> 6 μM




**CP-263,114**  
PFTase IC<sub>50</sub> 20 μM




**Rhombenone**  
PFTase IC<sub>50</sub> 2.3 μM




**Andrastin D**  
PFTase IC<sub>50</sub> 26 μM



57




58



FTI-276 R = H PFTase  $IC_{50}$  0.6 nM

FTI-277 R =  $CH_3$



GGTI-297 R = H PGGTase  $IC_{50}$  54 nM

GGTI-298 R =  $CH_3$

the most potent inhibitor isolated, with an  $IC_{50}$  of 430 nM vs. hr-PFTase; a more detailed kinetic analysis showed that, like Cylindrol A, compound **56** was non-competitive with respect to both Ras peptide and FPP substrates. A publication more fully describes the fungal metabolites **CP-225,917** and **CP-263,114**, the subjects of an earlier patent application [67]. These compounds inhibit PFTase with  $IC_{50}$  values of 6 and 20  $\mu$ M, respectively, but are only 7-fold selective for inhibition of PFTase over squalene synthase. A triterpene of the dammarane family, rhombenone, was isolated from the leaves of the medicinal plant *Hedera rhombea* bean, and was found to inhibit PFTase with an  $IC_{50}$  of 2.3  $\mu$ M [68]. A fourth member of the andrastin family of *penicillium* metabolites, andrastin

D, was isolated and characterised [69]. Andrastin D, similar to andrastins A-C, inhibited PFTase with an  $IC_{50}$  of 26  $\mu$ M. The steroid **57** [164] and tricyclic **58** [165] were claimed in a patent application from Merck as inhibitors of PFTase, although no biological data were given.

## 5. Conclusion

Activity both in the patent and scientific literature shows that interest in PFTase inhibitors remains high. Most of the current effort is focused on obtaining non-thiol PFTase inhibitors that can be administered orally, in anticipation that it will be necessary to maintain PFTase inhibition over extended periods of time. The recent publication of the x-ray crystal structure of rat PFTase should ultimately result in the design of novel PFTase inhibitors. As the first compounds move through clinical trials, basic research continues to elucidate fundamental aspects of protein prenylation and the biological consequences of suppressing protein prenylation.

## 6. Expert opinion

Results from clinical trials of the first generation of PFTase inhibitors will certainly inform and direct future research in the area. Important considerations include the choice of clinical markers to follow patient response, as well as clinical end-points to judge the success or failure of therapy. Combination therapy with other cancer drugs and a PFTase inhibitor will certainly be addressed. Coincident suppression of farnesylation and radiation therapy may impart added benefit, since **FTI-277** is reported to be a radiation sensitizer [70].

Given the differential binding of K-Ras to microtubules discussed earlier, it is reasonable to expect other physiological distinctions between H-, K-, and N-Ras proteins will appear. The effects of PFTase substrates other than Ras on cell growth and differentiation will also influence the direction of future research.

Additional biochemical studies need to define the role that protein geranylgeranylation plays in intracellular processes. Researchers at the University of Pittsburgh found that blocking PGGTase activity with the PGGTase inhibitor prodrug **GGTI-298** in either fibroblasts or human epithelial tumour cell lines affects cell cycle progression by stably arresting cells

in G<sub>0</sub>/G<sub>1</sub> [71-73]. It was also found that **GGTI-298** increased the expression of p21<sup>WAF</sup> independent of p53; p21<sup>WAF</sup> is a cyclin-dependent kinase inhibitor normally up-regulated by the p53 tumour suppressor protein in response to DNA damage. In contrast, the PFTase inhibitor prodrug **FTI-277** had either varying or no effect on cell cycle distribution, and did not induce the expression of p21<sup>WAF</sup>. Overall, these results suggest that a PGGTase inhibitor might be effective at inducing growth arrest in cells lacking functional p53. The relative influence of GGTase-I and PFTase inhibition in these experiments is not clear, however, since the active forms of **GGTI-298** (**GGTI-297**) and **FTI-277** (**FTI-276**) are equipotent GGTase-I inhibitors *in vitro* (IC<sub>50</sub> values 54 nM and 53 nM, respectively), differing only in their activity vs. PFTase (IC<sub>50</sub> values 190 nM and 0.6 nM, respectively) [71]. Clearly, PGGTase and PFTase inhibitors with greater selectivities are needed to elaborate on these results.

### Acknowledgements

The author would like to thank Sam Graham, George Hartman, Ian Bell, Doug Beshore, Chris Dinsmore and Craig Stump for helpful suggestions in the preparation of this review, and Joy Hartzell for her help in manuscript preparation.

### Bibliography

Papers of special note have been highlighted as:

- of interest
- of considerable interest

1. GRAHAM SL: **Inhibitors of protein farnesylation: a new approach to cancer chemotherapy.** *Exp. Opin. Ther. Patents* (1995) 5(12):1269-1285.
2. GRAHAM SL, WILLIAMS TM: **Inhibitors of protein farnesylation.** *Exp. Opin. Ther. Patents* (1996) 6(12):1295-1304.
3. OMER CA, KOHL NK: **CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.** *Trends Pharm. Sci.* (1997) 18:437-445.
4. SEPP-LORENZINO L, MA Z, RANDS E *et al.*: **A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines.** *Cancer Res.* (1995) 55:5302-5309.
  - This study demonstrated that the antiproliferative effects of a PFTase inhibitor in a panel of human tumour cell lines are independent of *ras* mutational status.
5. LERNER EC, ZHANG T-T, KNOWLES DB *et al.*: **Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CaaX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.** *Oncogene* (1997) 15:1283-1288.
  - One of the first indications that cross-prenylation of K-Ras by PGGTase renders K-*ras* transformed cells highly resistant to the effects of PFTase inhibition.
6. KOHL NE, OMER CA, CONNER MW *et al.*: **Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in *ras* transgenic mice.** *Nature Med.* (1995) 1:792-797.
  - The first study of a PFTase inhibitor in H-*ras* transgenic mice resulted in regression of the primary tumour mass.
7. BARRINGTON RE, SUBLER MA, RANDS E *et al.*: **A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.** *Mol. Cell Biol.* (1998) 18(1):85-92.
  - A study demonstrating that cells with multiple genetic lesions, such as are found in human cancer, are sensitive to the anti-proliferative effects of PFTase inhibitors.
8. LEBOWITZ PF, SAKAMURO D, PRENDERGAST GC: **Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.** *Cancer Res.* (1997) 57:708-713.
9. FOKSTUEN T, RABO YB, ZHOU J-N *et al.*: **The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line.** *Anticancer Res.* (1997) 17:2347-2352.
10. ROWELL CA, KOWALCZYK JJ, LEWIS MD, GARCIA AM: **Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras *in vivo*.** *J. Biol. Chem.* (1997) 272(22):14093-14097.
  - The observation that K-Ras can be geranylgeranylated *in vitro* by PGGTase I is demonstrated to occur *in vivo* in cell culture, under conditions where the farnesylation of K-Ras is suppressed by a PFTase inhibitor.
11. WHYTE DB, KIRSCHMEIER P, HOCKENBERRY TN *et al.*: **K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.** *J. Biol. Chem.* (1997) 272(22):14459-14464.
  - A second paper indicating that geranylgeranylation of K-Ras occurs in cell culture when protein farnesylation is blocked by a PFTase inhibitor.
12. THISSEN JA, GROSS JM, SUBRAMANIAN K, MEYER T, CASEY P: **Prenylation-dependent association of Ki-Ras with microtubules.** *J. Biol. Chem.* (1997) 272(48):30362-30370.
13. END D, SKRZAT S, DEVINE A *et al.*: **R115777, a novel farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-Ras and K-Ras dominant systems.** *Proc. Am. Assoc. Cancer Res.* (1998) 39:270. Abstract 1847.
14. ZUJEWSKI J, HORAK ID, WOESTENBORCHS R *et al.*: **Phase I trial of farnesyltransferase inhibitor, R115777, in advanced cancer.** *Proc. Am. Assoc. Cancer Res.* (1998) 39:270. Abstract 1848.
  - Initial results from the first clinical trial of a PFTase inhibitor.

15. LUI M, LEE S, YAREMKO B *et al.*: SCH 66336, an orally bioavailable tricyclic farnesyl protein transferase inhibitor, demonstrates broad and potent *in-vivo* antitumor activity. *Proc. Am. Assoc. Cancer Res.* (1998) **39**:270. Abstract 1843.
- Characterisation of SCH 66336, a PFTase inhibitor that entered human clinical trials in late 1997.
16. COWSERT LM: *In vitro* and *in vivo* activity of antisense inhibitors of *ras*: potential for clinical development. *AntiCancer Drug Design* (1997) **12**:359-371.
17. GIBBS JB, GRAHAM SL, HARTMAN GD *et al.*: Farnesyltransferase inhibitors versus Ras inhibitors. *Curr. Opin. Chem. Biol.* (1997) **1**(2):197-203.
18. COX AD, DER CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? *Biochim. Biophys. Acta* (1997) **1333**:F51-F71.
19. LEBOWITZ PF, CASEY PJ, PRENDERGAST GC, THISSEN JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of Rho-B. *J. Biol. Chem.* (1997) **272**(25):15591-15594.
- Evidence that RhoB is a PFTase substrate involved with cell proliferation.
20. FOSTER R, HU K-Q, LU Y, NOLAN KM, THISSAN J, SETTLEMAN J: Identification of a novel human Rho-protein with unusual properties - GTPase deficiency and *in vivo* farnesylation. *Mol. Cell. Biol.* (1996) **16**(6):2689-2699.
21. YAMAGATA K, SANDERS LK, KAUFMAN WE *et al.*: RheB, a growth factor-regulated and synaptic activity-regulated gene, encodes a novel Ras-related protein. *J. Biol. Chem.* (1994) **269**(23):16333-16339.
22. CLARK GJ, KINCH MS, ROGERSGRAHAM K *et al.*: The Ras-related protein RheB is farnesylated and antagonizes Ras signalling and transformation. *J. Biol. Chem.* (1997) **272**(16):10608-10615.
23. DIAMOND RH, CRESSMAN DE, LAZ TM, ABRAMS CS, TAUB R: PRL-1, a unique nuclear-protein tyrosine phosphatase, affects cell-growth. *Mol. Cell. Biol.* (1994) **14**(6):3752-3762.
24. CATES CA, MICHAEL RL, STAYBROOK KR *et al.*: Prenylation of oncogenic human PTPCAAX protein-tyrosine phosphatases. *Cancer Lett.* (1996) **110**:49-55.
25. DE SMEDT F, BOOM A, PESESSE X *et al.*: Posttranslational modification of human brain-type-I inositol-1,4,5-trisphosphate 5-phosphatase by farnesylation. *J. Biol. Chem.* (1996) **271**(17):10419-10424.
26. PARK H-W, BODULURI SR, MOOMAW JF, CASEY PJ, BEESE LS: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. *Science* (1997) **275**:1800-1804.
- The first crystal structure determination of PFTase.
27. PARK H-W, BEESE LS: Protein farnesyltransferase. *Curr. Opin. Struct. Biol.* (1997) **7**:873-880.
28. KRAL AM, DIEHL RE, DESOLMS SJ *et al.*: Mutational analysis of conserved residues of the  $\beta$ -subunit of human farnesyl:proteintransferase. *J. Biol. Chem.* (1997) **272**(43):27319-27323.
29. LEONARD DM: Ras farnesyltransferase - a new therapeutic target. *J. Med. Chem.* (1997) **40**(19):2971-2990.
30. REUVENI H, GITLER A, PORADOSU E, GILON C, LEVITZKI A: Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors. *Bioorg. Med. Chem.* (1997) **5**(1):85-92.
31. BURNS CJ, GUITTON J-D, BAUDOUIN B *et al.*: Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. *J. Med. Chem.* (1997) **40**(12):1763-1767.
32. CLERC F-F, GUITTON J-D, FROMAGE N *et al.*: Constrained analogs of KCVFM with improved inhibitory properties against farnesyl transferase. *Bioorg. Med. Chem. Lett.* (1995) **5**(16):1779-1784.
33. QIAN Y, BLASKOVICH MA, SALEEM M *et al.*: Design and structural requirements of potent peptidomimetic inhibitors of p21Ras farnesyltransferase. *J. Biol. Chem.* (1994) **269**:12410-12413.
34. QIAN Y, BLASKOVICH MA, SEONG CM *et al.*: Peptidomimetic inhibitors of p21Ras farnesyltransferase: hydrophobic functionalization leads to disruption of p21Ras membrane association in whole cells. *Bioorg. Med. Chem. Lett.* (1994) **4**(21):2579-2584.
35. BYK G, LELIEVRE Y, DUCHESNE M *et al.*: Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase. *Bioorg. Med. Chem.* (1997) **5**(1):115-124.
36. BYK G, DUCHESNE M, PARKER F *et al.*: Local constrained shifty pseudopeptides inhibitors of ras-farnesyl transferase. *Bioorg. Med. Chem. Lett.* (1995) **5**(22):2677-2682.
37. LEFTHERIS K: Highly potent thiol-based inhibitors of Ras farnesyl protein transferase. *25th National Medicinal Chemistry Symposium*. Ann Arbor, MI, USA (1996).
38. STOBBER P, SCHELHAAS M, NAGELE E *et al.*: Synthesis of characteristic lipopeptides of the human N-Ras protein and their evaluation as possible inhibitors of protein farnesyl transferase. *Bioorg. Med. Chem.* (1997) **5**(1):75-83.
39. DINSMORE CJ, WILLIAMS TM, HAMILTON K *et al.*: Diarylether inhibitors of farnesyl-protein transferase. *Bioorg. Med. Chem. Lett.* (1997) **7**(10):1345-1348.
40. VOGT A, YIMIN Q, BLASKOVICH MA *et al.*: A non-peptide mimic of Ras-CaaX: selective inhibition of farnesyltransferase and Ras processing. *J. Biol. Chem.* (1995) **270**(2):660-664.
41. QIAN Y, VOGT A, SEBTI SM, HAMILTON AD: Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors. *J. Med. Chem.* (1996) **39**:217-223.
42. MALLAMS AK, NJOROGUE FG, DOLL RJ *et al.*: Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, non-peptidic, nonsulfhydryl inhibitors of Ras farnesylation. *Bioorg. Med. Chem.* (1997) **5**(1):93-99.
43. NJOROGUE FG, DOLL RJ, VIBULBHAN V: Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase. *Bioorg. Med. Chem.* (1997) **5**(1):101-113.

44. MALLAMS AK, ROSSMAN RR, DOLL RJ *et al.*: Inhibitors of farnesyl protein transferase. part 2. 4-amido-, 4-carbamoyl and 4-carboxamido derivatives of 1-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine. *214th National American Chemical Society Meeting*. Las Vegas, NV (Sept. 7-11 1997).
45. NJOROGE FG, VIBULBHAN B, ALVAREZ CS: Novel tricyclic aminoacetyl and sulfonamide inhibitors of Ras farnesyl protein transferase. *Bioorg. Med. Chem. Lett.* (1996) 6(24):2977-2982.
46. LEONARD DM, SHULER KR, POULTER CJ *et al.*: Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit Ras farnesyltransferase. *J. Med. Chem.* (1997) 40(2):192-200.
47. SCHOLTEN JD, ZIMMERMAN KK, OXENDER MG *et al.*: Synergy between anions and farnesyl diphosphate competitive inhibitors of farnesyl:protein transferase. *J. Biol. Chem.* (1997) 272(29):18077-18081.
48. SCHOLTEN JD, ZIMMERMAN K, OXENDER M *et al.*: Inhibitors of farnesyl:protein transferase - a possible chemotherapeutic. *Bioorg. Med. Chem.* (1996) 4(9):1537-1543.
49. MCNAMARA DJ, DOBRUSIN E, LEONARD DM *et al.*: C-Terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of ras farnesyltransferase, cellular activity, and anticancer activity in mice. *J. Med. Chem.* (1997) 40(21):3319-3322.
50. WALLACE A, KOBLAN KS, HAMILTON K *et al.*: Selection of potent inhibitors of farnesyl-protein transferase from a synthetic tetrapeptide combinatorial library. *J. Biol. Chem.* (1996) 271(49):31306-31311.
51. GAON I, TUREK TC, DISTEFANO MD: Farnesyl and geranylgeranyl pyrophosphate analogs incorporating benzoylbenzyl ethers: synthesis and inhibition of yeast protein farnesyltransferase. *Tetrahedron Lett.* (1996) 37(49):8833-8836.
52. TUREK TC, GAON I, DISTEFANO MD: Analogs of farnesyl pyrophosphate incorporating internal benzoylbenzoate esters: synthesis, inhibition kinetics and photoinactivation of yeast protein farnesyltransferase. *Tetrahedron Lett.* (1996) 37(28):4845-4848.
53. GAON I, TUREK TC, WELLER VA *et al.*: Photoactive analogs of farnesyl pyrophosphate containing benzoylbenzoate esters: synthesis and application to photoaffinity labeling of yeast protein farnesyltransferase. *J. Org. Chem.* (1996) 61(22):7738-7745.
54. CROTEAU R, ALONSO WR, KOEPP AE, SHIM JH, CANE D: Irreversible inactivation of monoterpene cyclases by a mechanism-based inhibitor. *Arch. Biochem. Biophys.* (1993) 307(2):397-404.
55. GIBBS RA, KRISHNAN U, DOLENCE JM, POULTER CD: A stereoselective palladium copper-catalyzed route to isoprenoids - synthesis and biological evaluation of 13-methylidenefarnesyl diphosphate. *J. Org. Chem.* (1995) 60(24):7821-7829.
56. MU YQ, GIBBS RA, EUBANKS LM, POULTER CD: Cuprate-Mediated synthesis and biological evaluation of cyclopropyl- and *tert*-butylfarnesyl diphosphate analogs. *J. Org. Chem.* (1996) 61(23):8010-8015.
57. LINGHAM RB, SILVERMAN KC, BILLS GF *et al.*: Chaetomella acutisetata produces chaetomelic acids A and B which are reversible inhibitors of farnesyl-protein transferase. *App. Microbiol. Biotech.* (1993) 40(2-3):370-374.
58. SINGH SB, ZINK DL, LIESCH JM *et al.*: Isolation and structure of chaetomelic acids A and B from chaetomella acutisetatafarnesyl pyrophosphate mimic inhibitors of Ras farnesylprotein transferase. *Tetrahedron* (1993) 49(27):5917-5926.
59. RATEMI ES, DOLENCE JM, POULTER CD, VEDERAS JC: Synthesis of protein farnesyltransferase and protein geranylgeranyltransferase inhibitors: rapid access to chaetomelic acid A and its analogues. *J. Org. Chem.* (1996) 61(18):6296-6301.
60. JAYASURIYA H, BILLS GF, CASCALES C *et al.*: Oreganic acid: a potent novel inhibitor of Ras farnesyl-protein transferase from an endophytic fungus. *Bioorg. Med. Chem. Lett.* (1996) 6(17):2081-2084.
61. SILVERMAN KC, JAYASURIYA H, CASCALES C *et al.*: Oreganic acid, a potent inhibitor of Ras farnesyl-protein transferase. *Biochem. Biophys. Res. Comm.* (1997) 232(2):478-481.
62. KAMINSKI JJ, RANE DF, SNOW ME *et al.*: Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods. *J. Med. Chem.* (1997) 40(25):4103-4112.
63. UCHIDA R, SHIOMI K, INOKOSHI J *et al.*: Kurasoins A and B, new protein farnesyltransferase inhibitors produced by *Paecilomyces* sp. FO-3684. I. producing strain, fermentation, isolation, and biological activities. *J. Antibiot.* (1996) 49(9):932-934.
64. UCHIDA R, SHIOMI K, SUNAZUKA T *et al.*: Kurasoins A and B, new protein farnesyltransferase inhibitors produced by *Paecilomyces* sp. FO-3684. II. Structure elucidation and total synthesis. *J. Antibiot.* (1996) 49(9):886-889.
65. SUNAZUKA T, HIROSE T, ZHI-MING T *et al.*: Synthesis and absolute structures of novel protein farnesyltransferase inhibitors, kurasoins A and B. *J. Antibiot.* (1997) 50(5):453-455.
66. SINGH SB, BALL RG, BILLS GF *et al.*: Chemistry and biology of cylindrols: novel inhibitors of Ras farnesyl-protein transferase from *Cylindrocarpum lucidum*. *J. Org. Chem.* (1996) 61(22):7727-7737.
67. DABRAH TT, HARWOOD HJ, HUANG LH *et al.*: CP-225,917 and CP-263,114, novel Ras farnesylation inhibitors from an unidentified fungus. I. Taxonomy, fermentation, isolation, and biochemical properties. *J. Antibiot.* (1997) 50(1):1-6.
68. KWON B-M, LEE S-H, KIM K-S *et al.*: Rhombenone: farnesyl protein transferase inhibitor from the leaves of *Hedera Rhombea* bean. *Bioorg. Med. Chem. Lett.* (1997) 7(8):971-974.

## 568 Inhibitors of protein farnesylation 1998

69. UCHIDA R, SHIOMI K, INOKOSHI J, TANAKA H, IWAI Y, OMURA S: **Andrastatin D, novel protein farnesyltransferase inhibitor produced by *Penicillium* sp. FO-3929.** *J. Antibiot.* (1996) 49:1278-1280.
70. BERNHARD EJ, KAO G, COX AD *et al.*: **The farnesyltransferase inhibitor FTI-277 radiosensitizes H-Ras-transformed rat embryo fibroblasts.** *Cancer Res.* (1996) 56:1727-1730.
71. VOGT A, QUIAN Y, MCGUIRE TF, HAMILTON AD, SEBTI SM: **Protein geranylgeranylation, not farnesylation, is required for the G<sub>1</sub> to S phase transition in mouse fibroblasts.** *Oncogene* (1996) 13:1991-1999.
72. VOGT A, SUN J, QUIAN Y, HAMILTON AD, SEBTI SM: **The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G<sub>0</sub>/G<sub>1</sub> and induces p21<sup>WAF1/CIP1/SDI1</sup> in a p53-independent manner.** *J. Biol. Chem.* (1997) 272(43):27224-27229.
73. MIQUEL K, PRADINES A, SUN J *et al.*: **GGTI-298 induces G<sub>0</sub>-G<sub>1</sub> block and apoptosis whereas FTI-277 causes G<sub>2</sub>-M enrichment in A549 cells.** *Cancer Res.* (1997) 57:1846-1850.

## Patents

- |  |  |
|--|--|
| 101. MERCK & CO., INC.: US5536750 (1996).        | 124. MERCK & CO., INC.: WO9736593 (1997).        |
| 102. RHÔNE-POULENC RORER SA: WO9703047 (1997).   | 125. MERCK & CO., INC.: WO9736888 (1997).        |
| 103. ZENECA, LTD.: WO9706138 (1997).             | 126. MERCK & CO., INC.: WO9736889 (1997).        |
| 104. MERCK & CO., INC.: WO9630014 (1996).        | 127. MERCK & CO., INC.: WO9718813 (1997).        |
| 105. BIOMEASURE, INC.: WO9730053 (1997).         | 128. MERCK & CO., INC.: WO9736605 (1997).        |
| 106. MERCK & CO., INC.: WO9631525 (1996).        | 129. MERCK & CO., INC.: WO9736900 (1997).        |
| 107. UNIV. PITTSBURGH: WO9717070 (1997).         | 130. MERCK & CO., INC.: WO9736892 (1997).        |
| 108. SCHERING CORP.: WO9630018 (1996).           | 131. MERCK & CO., INC.: WO9736875 (1997).        |
| 109. SCHERING CORP.: WO9630317 (1996).           | 132. MERCK & CO., INC.: WO9736811 (1997).        |
| 110. SCHERING CORP.: WO9630362 (1996).           | 133. MERCK & CO., INC.: WO9736886 (1997).        |
| 111. SCHERING CORP.: WO9630363 (1996).           | 134. MERCK & CO., INC.: WO9736890 (1997).        |
| 112. SCHERING CORP.: WO9631477 (1996).           | 135. MERCK & CO., INC.: WO9736896 (1997).        |
| 113. SCHERING CORP.: WO9631478 (1996).           | 136. MERCK & CO., INC.: WO9736897 (1997).        |
| 114. PHARMACOPEIA: WO9631505 (1996).             | 137. MERCK & CO., INC.: WO9736898 (1997).        |
| 115. SCHERING CORP.: WO9631501 (1996).           | 138. MERCK & CO., INC.: WO9736901 (1997).        |
| 116. WARNER-LAMBERT CO.: WO9744350 (1997).       | 139. MERCK & CO., INC.: WO9736897 (1997).        |
| 117. WARNER-LAMBERT CO.: WO9726246 (1997).       | 140. MERCK & CO., INC.: WO9639137 (1996).        |
| 118. JANSSEN PHARMACEUTICA NV: WO9716443 (1997). | 141. MERCK & CO., INC.: WO9727752 (1997).        |
| 119. JANSSEN PHARMACEUTICA NV: WO9721701 (1997). | 142. MERCK & CO., INC.: WO9727853 (1997).        |
| 120. MERCK & CO., INC.: WO9637204 (1996).        | 143. MERCK & CO., INC.: WO9727854 (1997).        |
| 121. MERCK & CO., INC.: WO9736891 (1997).        | 144. MERCK & CO., INC.: WO9736583 (1997).        |
| 122. MERCK & CO., INC.: WO9630343 (1996).        | 145. MERCK & CO., INC.: WO9736584 (1997).        |
| 123. MERCK & CO., INC.: WO9736591 (1997).        | 146. MERCK & CO., INC.: WO9736876 (1997).        |
|  | 147. MERCK & CO., INC.: WO9736877 (1997).        |
|  | 148. BRISTOL-MYERS SQUIBB CO.: WO9730992 (1997). |
|  | 149. PFIZER, INC.: EP-760239-A2 (1997).          |
|  | 150. PFIZER, INC.: EP-810223-A1 (1997).          |
|  | 151. WARNER-LAMBERT CO.: WO9700252 (1997).       |
|  | 152. RHÔNE-POULENC RORER SA: WO9703050 (1997).   |
|  | 153. BANYU PHARM. CO. LTD.: WO9617623 (1996).    |
|  | 154. BANYU PHARM. CO. LTD.: WO9705902 (1997).    |
|  | 155. BANYU PHARM. CO. LTD.: WO9717321 (1997).    |
|  | 156. BANYU PHARM. CO. LTD.: WO9729073 (1997).    |
|  | 157. BANYU PHARM. CO. LTD.: WO9729074 (1997).    |
|  | 158. BANYU PHARM. CO. LTD.: WO9729075 (1997).    |
|  | 159. BANYU PHARM. CO. LTD.: WO9729077 (1997).    |
|  | 160. BANYU PHARM. CO. LTD.: WO9729078 (1997).    |
|  | 161. ABBOTT LAB.: WO9633159 (1996).              |
|  | 162. ABBOTT LAB.: WO9634850 (1996).              |
|  | 163. ABBOTT LAB.: WO9634852 (1996).              |
|  | 164. MERCK & CO., INC.: WO9635707 (1996).        |

165. MERCK & CO., INC.: WO9705270 (1997).

### References to the internet

---

201. [http://cancernet.nci.nih.gov/cgi-bin/cancer-phy\\_show](http://cancernet.nci.nih.gov/cgi-bin/cancer-phy_show)

---

Theresa M Williams  
Department of Medicinal Chemistry, Merck Research Laboratories,  
West Point, PA 19438, USA